Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed)
This grant will fund projects to develop new technologies for identifying and targeting senescent cells in human tissues to better understand their role in health and disease and advance therapies.
Funder: National Institutes of Health
Due Dates: November 23, 2026 (Application deadline)
Funding Amounts: $6,000,000 estimated total program funding; 15 expected awards; five-year projects
Summary: Supports development or adaptation of technologies to identify and characterize senescent cell heterogeneity and understand its consequences in aging and disease.
Key Information: Applicants must submit both UG3 and UH3 projects together; clinical trials are not allowed.
Description
The National Institutes of Health’s Cellular Senescence Network (SenNet) supports innovative senescence technologies (SenTecs), including adaptations of existing technologies. Projects focus on identifying and characterizing senescent cell heterogeneity and understanding its biological consequences within tissue environments and secretomes. The goal is to facilitate new strategies for modulating senescent cells in vivo and predicting the outcomes of targeting these cells in human aging and disease.
These milestone-driven cooperative agreements span two phases. The first two years support technology development and demonstration of feasibility under the UG3 phase. The subsequent three-year UH3 phase supports continued optimization, refinement, and validation. In the final year, awardees undertake a collaborative demonstration project within SenNet to further validate their technology.
